About Integris Medtech IPO
The Integris Medtech IPO is planned to go public with SEBI on October 9, 2025, documenting a DRHP, a 100% book-built issue, a primary equity share fresh issue of ₹925 crores, and an offer for sale (OFS) of 21,674,531 equity shares.
The price band and official subscription dates will be announced later. Each equity share has a face value of ₹1 and will be listed on the BSE and NSE. Book Running Lead Managers (BRLMs) are ICICI Securities Ltd., Axis Capital Ltd., Citigroup Global Markets India Private Ltd., and IIFL Capital Services. KFin Technologies Ltd. will serve as the offer registrar.
Company Background
Integris Medtech Ltd. was incorporated on April 25, 2008, as Integris Health Private Limited and changed its name to Integris Medtech Private Limited in June 2025, before becoming a public limited company in August 2025.
The company is headquartered in Noida, Uttar Pradesh, with a registered office in New Delhi and a corporate office in Noida. It has expanded its operations to over 65 countries as of June 30, 2025.
Operations and Product Range
Integris Medtech Ltd. is a global provider of laboratory solutions and medical products. It develops, manufactures, and sells a fully integrated portfolio across several medical segments:
- • Cardiovascular Devices: Premium devices for heart-related medical procedures.
- • Clinical Diagnostics: Devices for medical testing and disease-related diagnostics.
- • Scientific Laboratory Solutions: Sophisticated devices for research and clinical laboratories.
The company sells directly to healthcare professionals and has reached over 550 cardiologists across 250 centers within one year for specific product launches.
Facilities and Capacity
Integris Medtech has manufacturing facilities in India, Germany, and the Netherlands. These support the company’s diverse product range and global regulatory compliance, particularly for IVD products.
Brands and Market Presence
Integris Medtech has established a strong presence with flagship products, including the Protégé paclitaxel-coated balloon launched in 2024. The company created the "Minimal Metal Plasty" (MMP) market and achieved the #3 position in the Indian drug-coated balloon (DCB) market within one year. Its products are now distributed in over 65 countries.
Revenue Streams and Business Model
Revenue is generated from three main segments: cardiovascular, clinical diagnostics, and scientific laboratory solutions. For FY2025, revenue from operations was ₹2,332.81 Cr on a pro forma basis. The business model focuses on high-throughput and automated solutions, with significant revenue from global sales in the Americas, Europe, and Asia Pacific.
Management and Shareholding
Promoters include Evercure Holdings Pte. Ltd., Medicore Holdings Pte. Ltd., Gurmit Singh Chugh, and Punita Sharma. Before the IPO, the promoters and promoter group held a significant equity portion. The OFS component will dilute a portion of promoter stakes, while fresh capital will fund company expansion.
Board and Key Management
The board is led by promoters Gurmit Singh Chugh and Punita Sharma, with Darpan Batra as Group General Counsel and Compliance Officer, ensuring compliance with SEBI and Companies Act regulations while monitoring strategic initiatives.
Integris Medtech IPO Details
| Detail | Description |
|---|---|
| IPO Date | [.] |
| Listing Date | [.] |
| Face Value | ₹ 1 per Equity Share |
| Issue Price Band | [.] |
| Lot Size | [.] |
| Sale Type | Book Built Issue |
| Total Issue Size | [.] |
| Fresh Issue(Ex Market Maker) | Up to ₹ 925.00 Crore (₹9,250.00 Million) |
| Offer for Sale | Up to 2,16,74,531 Equity Shares |
| Issue Type | 100 % Book Built Offer |
| Listing At | BSE and NSE |
| Share Holding Pre Issue | 10,83,38,049 shares |
Integris Medtech IPO Financial Information
Latest Revenue
508.93
₹ Crore
Profit After Tax
267.57
₹ Crore
Net Worth
1,807.82
₹ Crore
Total Borrowing
832.14
₹ Crore
| Period Ended | Assets | Revenue From Operations | Profit After Tax | Net Worth | Reserves & Surplus | Total Borrowing | |||
|---|---|---|---|---|---|---|---|---|---|
| 30 Jun 2025 | 3,340.40 | 508.93 | 267.57 | 1,807.82 | 1,804.85 | 832.14 | |||
| 31 Mar 2025 | 3,106.88 | 1,959.58 | 70.68 | 1,532.74 | 1,530.04 | 1,029.02 | |||
| 31 Mar 2024 | 2,988.58 | 1,582.26 | (4.88) | 318.99 | 316.29 | 614.32 | |||
| 31 Mar 2023 | 2,560.20 | 1,369.66 | (40.54) | 188.58 | 161.52 | 423.41 | |||
| Amount in ₹ Crore | |||||||||
Integris Medtech Key Performance Indicator
| KPI | Values |
|---|---|
| ROE | 1.84% |
| ROCE | 1.84% |
| Debt/Equity | 0.67x |
| PAT Margin | 3.72% |
| EBITDA Margin | 16.26% |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | ₹0.85 | [.] |
| P/E (x) | [.] | [.] |
IPO Objectives
The proceeds from the fresh issue are intended for strategic uses, including:
- • Repayment of debt (full or partial).
- • General corporate purposes.
Conclusion
Integris Medtech Ltd. is a significant global player in medical technology and laboratory solutions, with a manufacturing presence in India and Europe and a rapidly growing domestic market share in high-end cardiovascular devices.
The IPO represents a major milestone, enhancing the company’s valuation, scalability, and credibility. Its balanced focus on R&D, global exports, and domestic leadership supports its strategic execution in the evolving healthcare landscape.
Frequently Asked Questions
Recommended Advisory Services
Ready to take your company public? Explore our specialized IPO advisory services tailored for Indian enterprises.
The India IPO Publication is managed by an editorial team that includes highly experienced finance journalists, market researchers and professionals from the capital markets industry who strive to create high-quality content based on credible sources. Our editors write about IPOs, capital markets, corporate news, capital-raising strategies, regulations and other business matters to ensure our audience stays updated with the latest information. We conduct detailed research and fact-check all information before publishing any content to ensure credibility.
Competitive Strengths
Experience in creating and marketing an integrated portfolio of medical devices and laboratory solutions in 65+ countries.
The presence of operational facilities in India, Germany and the Netherlands ensures a strong supply chain to support the global market.
Ability to rapidly gain market share, as evidenced by the achievement of the #3 position in the Indian DCB market within a year.
| Sr.no | Description | Date | File |
|---|---|---|---|
| 1 | Filed with SEBI/Exchange | 09/10/2025 | - |
| 2 | SEBI/Exchange approval received | - | - |
Integris Medtech IPO Timeline
| IPO Open Date | [.] |
| IPO Close Date | [.] |
| Tentative Allotment | [.] |
| Initiation of Refunds | [.] |
| Credit of Shares to Demat | [.] |
| Tentative Listing Date | [.] |
| Cut-off time for UPI mandate confirmation | - |
IPO Lot Size
| Investors | No.of lots | Shares Offered | Max Bid Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 1 | [.] | ₹14,000 - ₹15,000 |
| Individual investors (Retail) (Max) | 13-14 | [.] | Up to ₹2,00,000 |
| S-HNI (Min) | 14-15 | [.] | Over ₹2,00,000 |
| S-HNI (Max) | 66-70 | [.] | Up to ₹10,00,000 |
| B-HNI (Min) | 71+ | [.] | Over ₹10,00,000 |